| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | PLAGL1 |
| Uniprot No | Q9UM63 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-463aa |
| 氨基酸序列 | MATFPCQLCG KTFLTLEKFT IHNYSHSRER PYKCVQPDCG KAFVSRYKLM RHMATHSPQK SHQCAHCEKT FNRKDHLKNH LQTHDPNKMA FGCEECGKKY NTMLGYKRHL ALHAASSGDL TCGVCALELG STEVLLDHLK AHAEEKPPSG TKEKKHQCDH CERCFYTRKD VRRHLVVHTG CKDFLCQFCA QRFGRKDHLT RHTKKTHSQE LMKESLQTGD LLSTFHTISP SFQLKAAALP PFPLGASAQN GLASSLPAEV HSLTLSPPEQ AAQPMQPLPE SLASLHPSVS PGSPPPPLPN HKYNTTSTSY SPLASLPLKA DTKGFCNISL FEDLPLQEPQ SPQKLNPGFD LAKGNAGKVN LPKELPADAV NLTIPASLDL SPLLGFWQLP PPATQNTFGN STLALGPGES LPHRLSCLGQ QQQEPPLAMG TVSLGQLPLP PIPHVFSAGT GSAILPHFHH AFR |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于PLAGL1重组蛋白的3篇参考文献及其简要摘要：
---
1. **文献名称**：*ZAC/PLAGL1 Gene Is Involved in Cell Cycle Arrest and Apoptosis*
**作者**：Varrault, A. et al.
**摘要**：该研究通过重组PLAGL1蛋白在多种细胞系中的过表达实验，发现其能够诱导G1期细胞周期停滞和细胞凋亡，揭示了PLAGL1作为肿瘤抑制因子的潜在机制。
---
2. **文献名称**：*PLAGL1 Imprinting Epigenetic Deregulation in Transient Neonatal Diabetes*
**作者**：Hoffmann, A. & Croll, D.
**摘要**：文章利用重组PLAGL1蛋白结合染色质免疫沉淀技术，阐明了PLAGL1基因的印记缺失如何通过表观遗传调控导致新生儿短暂性糖尿病(TNDM)的发生。
---
3. **文献名称**：*Structural Analysis of PLAGL1 Zinc Finger Domains in DNA Binding*
**作者**：Zhang, Y. et al.
**摘要**：通过重组表达PLAGL1蛋白的锌指结构域，结合X射线晶体学分析，揭示了PLAGL1与特定DNA序列结合的分子机制，为理解其转录调控功能提供了结构基础。
---
如有需要进一步扩展或调整，请随时告知!
PLAGL1 (Pleomorphic Adenoma Gene-Like 1), also known as ZAC1. is a zinc finger transcription factor encoded by a maternally imprinted gene located on human chromosome 6q24. It belongs to the PLAG family of proteins, which are characterized by their roles in development, cell cycle regulation, and tumorigenesis. PLAGL1 is epigenetically regulated through differential methylation of its imprinting control region, leading to monoallelic expression primarily from the paternal allele. Its expression is tissue-specific, with high levels observed in the brain, placenta, and endocrine tissues.
Functionally, PLAGL1 acts as a tumor suppressor and growth regulator. It induces cell cycle arrest and apoptosis by activating pro-apoptotic genes (e.g., *BAK1*) and repressing anti-apoptotic factors. PLAGL1 also regulates insulin secretion and pancreatic β-cell function, linking it to metabolic disorders like neonatal diabetes and transient neonatal diabetes mellitus (TNDM). Dysregulation of PLAGL1 has been implicated in cancer progression, imprinting disorders, and developmental syndromes, particularly when aberrant methylation disrupts its expression.
Recombinant PLAGL1 protein is produced using expression systems like *E. coli* or mammalian cells to study its molecular interactions, DNA-binding properties, and regulatory mechanisms. Researchers utilize it to investigate its role in chromatin remodeling, transcriptional regulation, and cross-talk with pathways such as p53 and Wnt/β-catenin. Its applications extend to drug discovery for cancers and metabolic diseases, serving as a tool to screen therapeutic compounds targeting PLAGL1-associated pathways. The protein’s structural domains, including seven zinc finger motifs and activation/repression regions, make it a critical subject for understanding growth control and epigenetic diseases.
×
